Related Experiment Video
Updated: Nov 26, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
Combined-Indications Significance Level of Multiple Related Indications Developed Simultaneously
Jiacheng Yuan1, Ray Zhu2, Daniel Jia3
1Allergan Inc, 2525 Dupont Drive, MI2-2D, Irvine, CA, 92612, USA. jiacheng.yuan@allergan.com.
Developing multiple related indications simultaneously for drug approval can be more efficient. This approach allows for a less stringent combined-studies significance level compared to traditional sequential development.
Area of Science:
- Pharmaceutical Sciences
- Biostatistics
- Drug Development
Background:
- Regulatory approval typically requires two confirmatory studies per indication, each at a one-sided 0.025 significance level.
- Existing approvals for related indications can sometimes allow for one confirmatory study for a new indication.
Purpose of the Study:
- To explore strategies for simultaneous development of multiple related drug indications.
- To maintain a desired combined-studies significance level while streamlining the approval process.
Main Methods:
- The study proposes statistical frameworks for evaluating multiple indications concurrently.
- It does not involve human or animal subject studies.
Main Results:
- Strategies are presented for simultaneous indication development, allowing for a less stringent overall significance level.
- An example strategy involves a combined-studies significance level of one-sided 0.0000156 for two indications, with individual studies at 0.00395.
Conclusions:
- Simultaneous development of related indications is feasible for marketing registration.
- This approach can achieve regulatory approval with a more lenient combined-studies significance level than the standard two-study paradigm per indication.
More Related Videos
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
Significance Testing: Overview
Bonferroni Test
The means of different samples are first paired in all possible combinations.
The null hypothesis of the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Critical Region, Critical Values and Significance Level
In hypothesis testing, a sample statistic is converted to a test statistic using z, t, or chi-square distribution. A critical region is an area under the curve in probability distributions demarcated by the critical value. When the test statistic falls in this region, it suggests that the null hypothesis must be rejected. As this region contains all those values of the...